R J Mullin Selected Research

N- (3- chloro- 4- ((3- fluorobenzyl)oxy)phenyl- 6- (5- ((methylsulfonyl)ethyl)aminomethyl)- 2- furyl)- 4- quinazolinamine

12/2001

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

R J Mullin Research Topics

Disease

2	Neoplasms (Cancer) 12/2001 - 10/2001

Drug/Important Bio-Agent (IBA)

2	Phosphotransferases (Kinase)IBA 12/2001 - 10/2001
2	Tyrosine Kinase InhibitorsIBA 12/2001 - 10/2001
1	ErbB Receptors (EGF Receptor)IBA 12/2001
1	N- (3- chloro- 4- ((3- fluorobenzyl)oxy)phenyl- 6- (5- ((methylsulfonyl)ethyl)aminomethyl)- 2- furyl)- 4- quinazolinamineIBA 12/2001
1	Tyrosine (L-Tyrosine)FDA Link 12/2001
1	tyrosine receptor (receptor, tyrosine)IBA 10/2001
1	Proteins (Proteins, Gene)FDA Link 10/2001

Therapy/Procedure

2	Therapeutics 12/2001 - 10/2001